Dr Guy Pratt is an Honorary Consultant Haematologist at the Heart of England NHS Foundation Trust and Senior Lecturer in Haematology in the School of Cancer Sciences, University of Birmingham.
Dr Pratt has been a Consultant Haematologist in Birmingham since 2001 as a joint appointment working both at the Heart of England NHS Trust as an Honorary NHS Consultant and at the Institute for Cancer Studies in the University of Birmingham as a University Senior Lecturer. His main research interests are multiple myeloma and chronic lymphocytic leukaemia and he is actively involved in supporting basic research, in developing guidelines and in clinical trials in these diseases.
He has a growing publication output with 70+ peer reviewed publications and is currently chief investigator for a national phase I/II trial of a parp inhibitor in CLL. He is actively involved in teaching and mentoring of medical students. At the Heart of England NHS Trust Dr Pratt is currently Trust chemotherapy lead and Lead Clinician for Haematology, leading the MDT team.
Dr Guy Pratt graduated from Cambridge University in 1989. Following junior doctor training in London he specialized as a specialist registrar in Haematology in Liverpool and Leeds. He completed an MD thesis looking at the genetic events in multiple myeloma patients In Leeds.
As a Consultant Haematologist, he has 6 planned NHS sessions and works as one of eight Consultant Haematologists in the Heart of England NHS Trust that includes Birmingham Heartlands Hospital (Level 4 allogeneic transplantation), Good Hope Hospital (Level 1) and Solihull Hospital. His particular interest is Haemato-Oncology, in particular multiple myeloma and CLL but is involved in all aspects of general Haematology and provides an equal clinical commitment for inpatient take, ward rounds, laboratory reporting and 2-3 weekly outpatient sessions.
The department provides a comprehensive service for the local population (currently over 750000) and receives tertiary referrals throughout the West Midlands for patients requiring intensive chemotherapy/bone marrow transplant services. In clinical Haematology the department is involved in >25 clinical studies and is the largest contributor to national studies within the West Midlands. The department was rewarded with the Charter Mark in November 2002.
His main research interests are multiple myeloma and chronic lymphocytic leukaemia and include T cell immunity, genetic polymorphisms and exploring biomarkers in these diseases. He is chief investigator for a national trial of a parp inhibitor in CLL. He regularly peer reviews for a number of journals, grant holders and has acted as an external examiner. He has developed a large number of collaborations nationally with a growing publication output and is involved in the publication of national myeloma guidelines.
His responsibilities include:
Lead Clinician for Haematology at HEFT, MDT lead, 2002 to present, Deputy Pan-Birmingham Network Haematology NSSG Chair – Acting Chair for maternity leave June 2007-January 2009, UK Myeloma Forum Secretary for Guidelines Group, Trust Chemotherapy Lead 2002 to present, Lead for Wednesday morning Lymphoma/Myeloma/CLL clinic, Co- Lead for molecular Haematology Laboratory at Heartlands Hospital (report all molecular results), lead for the West Midlands CLL/Multiple Myeloma research subgroup. Graduate Studies Committee for Cancer Sciences
Guy Pratt is keen to support and stimulate Haematology research. His main interests are as follows:
His original MD in Leeds was looking at the genetics of chromosomal translocations in Mulitple Myeloma. His main interests have been in characterising tumour specific CD8+ and CD4+ T cells responses and the T cell disturbance in blood and bone marrow in a large cohort of patients with plasma cell disorders. More recent work involves characterising differences in the tumour cell microenvironment in multiple myeloma and the premalignant MGUS state. He is a co-investigator for a NIHR-HTA supported national study (for £1900000) examining Prophylactic antibiotics in myeloma trial (Tackling early morbidity in myeloma -TEAMM).
Chronic Lymphocytic Leukaemia
He is chief investigator for the a national trial supported by the Leukaemia Research Fund (£305000) and free drug supplied by Astra Zeneca - Phase I/II clinical trial to assess the efficacy and safety of the drug olaparib, a PARP-inhibitor, in relapsed and refractory Chronic Lymphocytic Leukaemia, Mantle cell and T prolymphocytic leukaemia patients with an 11q deletion. This study is based on the laboratory work of Dr T. Stankovic on ATM in CLL and the development of olaparib by Kudos/Astra Zeneca.
He has developed national and industry based collaborations with the following groups
Chris Bunce/Mark Drayson. (Biosciences, University of Birmingham) -investigating the effects of Bezafibrate and medroxyprogesterone and other novel agents in CLL in vitro.
Dr Chris Fegan, Dr Chris Pepper, Dr Paul Brennan, Dr Duncan Baird. (University of Wales, Cardiff). Investigating the role of Mcl-1, Zap-70, NF-kb, BCR signalling, CD38 and telomere dysfunction in CLL biology.
Dr Jim Allan (Newcastle University)/David Allsup (Hull Royal Infirmary) Investigating polymorphisms in CLL and multiple myeloma.
UK-wide genome association studies in CLL
A collaborative effort from a number of UK CLL groups led by Richard Houlston (Institute for Cancer Research, Royal Marsden) publishing twice in Nature Genetics in 2008 and 2010.
Binding Site UK Ltd, Birmingham, UK
His interests include looking at the kinetics of serum free light chains (FLC) as a rapid marker of response in multiple myeloma and at the prognostic importance of serum FLC in chronic lymphocytic leukaemia and lymphoma.
Dr Julio Delgado (Barcelona)
Studies looking at the impact of infections in CLL, reduced intensity conditioning transplants in CLL and prognostic factors.
Dr Mark Cobbold (Immunity and Infection, University of Birmingham)
Mark is the PI for a Kay Kendall Leukaemia Fund Project Grant 2008-2010: Immune targeting of the phosphoproteome in chronic lymphocytic leukaemia.
Guy Pratt is a co-applicant on this grant along with Dr Tanja Stankovic
Prof Tanja Stankovic/Prof Malcolm Taylor (Cancer Sciences, University of Birmingham)
Studies looking at the biology of ATM mutated CLL and ATM in Multiple Myeloma. Recently obtained a £7000 BSH start up grant to look at PTEN dysfunction in CLL. Part of a consortium that bid successfully for two PhD students in 2011 led by Prof Taylor.
Professor Paul Moss (Cancer Sciences, University of Birmingham)
Two CLL projects: CLL in Asians (Study looking at the demographics and biology of CLL in the West Midlands UK Asian population) and studies looking at T cell immunity in CLL.
Majid A, Lin TT, Best G, Fishlock K, Hewamana S, Pratt G, Yallop D, Buggins AG, Wagner S, Kennedy BJ, Miall F, Hills R, Devereux S, Oscier DG, Dyer MJ, Fegan C, Pepper C (2010) CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res Epub
Hutchison CA, Pratt G (2010) Free light chains and renal disorders: when small is worse. Lancet 376, 1220
Weston VJ, Oldrieve CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116, 4578-4587
Hayden RE, Pratt G, Drayson MT, Bunce CM (2010). Lycorine sensitizies CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibbrate- and medroxyprogesterone acetate induced apoptosis but dasatinib does not overcome reported CD40-mediated drug resistance. Haematologica 95, 1889-1896
Smith HJ, Hanvesakaul R, Morgan MD, Bentall A, Briggs D, Clark F, Pratt G, Moss P, Larche M, Ball S (2010). Chronic Graft versus host disease is associated with an immune response to autologous human leukocyte antigen-derived peptides. Transplantation 90, 555-563
Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, Fegan C, Pepper C, Baird DM (2010). Telomere dysfunction and fusion during the progression of a human malignancy. Blood 116, 1899-1907
Walsby EJ, Pratt G, Hewamana S, Crooks PA, Burnett AK, Fegan C, Pepper C (2010). The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Mol Cancer Ther. 9, 1574-1582.
McLarnon A, Piper K, Goodyear O, Arrazi J, Mahendra P, Cook M, Clark F, Pratt G, Craddock C, Moss P (2010). CD8+ T cell immunity against cancer testis antigens develops following allogeneic stem cell transplantation and reveals a novel mechanism for graft versus leukaemia. Haematologica 95, 1572-1578